Table 1. Clinical and demographic features of patients with neuromyelitis optica and controls.
| Patients, n = 28 | Controls, n = 28 | P Value | ||
| Age a | 45.3 years (11.7) | 42 (15.6) | >.05 | |
| Years of education a | 12.2 (2.9) | 12.9 (3.4) | >.05 | |
| Female/male | 19/9 | 19/9 | >.05 | |
| EDSS score b | 3.42 (0–6.5) | NA | NA | |
| Disease duration (years) aImmunosuppressant treatment cImmunomodulatory treatment c | 11.9 (10.9)152 | NANANA | NANANA | |
| First signs | Optic neuritis (n = 17), myelitis (n = 8), optic neuritis and myelitis (n = 2), brainstem signs (n = 1) | NA | NA | |
| NMO-IgG+(%) | 12 (43) | NA | NA | |
| CSF | Protein (g/l) | 0.51 | NA | NA |
| White cells/mm3a | 27.0 (45.2) | NA | NA | |
| Positive IgG (%) OCB | 18 | NA | NA | |
a
mean (standard deviation);
b
median (range); EDSS = Expanded Disability Status Scale;
c
At the time of cognitive tests and brain MRI. OCB = oligoclonal bands
NA = not applicable.